Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided
cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast
cancer patients undergoing treatment with doxorubicin, trastuzumab, or the combination.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania